FL-SATO-GLOBAL-SOLUTIONS
SATO Global Solutions (SGS), an innovation integrator that develops comprehensive Internet of Things (IoT) solutions designed to unleash the power of data, has collaborated with Intel to develop a data-driven, end-to-end IoT platform that enables retailers to accelerate the commercial benefit of data and IoT with a new level of actionable insight.
The solution allows retailers to realize near 100% inventory accuracy while boosting workforce efficiency. Additionally, it enables digital engagement applications to bring cutting edge and innovative retail experiences to consumers.
“Integrating near-real-time inventory data and customer data opens up new possibilities—allowing retailers to provide highly personalized and effective services to customers. This may include everything from offering extra discounts to loyal customers on overstocked items to using digital signage to push sales based on trending data from social media,” said Michael Beedles, president of SATO Global Solutions, "We are excited to pioneer new products and services with Intel. As an 'Innovation Integrator,' SGS develops future-proof expandable platforms to leverage optimal technologies to address clients’ needs.”
“By using the new Intel® Retail Sensor Platform, SATO Global Solutions can help deliver simple, affordable, effective inventory tracking and insight for retailers to improve consumer experiences and reduce operating costs solutions,” said Joe Jensen, VP, Intel Internet of Things Group General Manager, Retail Solutions Division.
The platform seamlessly integrates a range of retail technologies including RFID readers that track individual items in the store, the ability to leverage additional sensors with the Intel® Retail Sensor Platform, a store-based gateway that gathers and filters data, a robust cloud platform and big data analytics. The SGS IoT platform integrates these components into a comprehensive retail solution that standardizes the collection, storage, and analytics for store-based events involving inventory and customer interactions.
Designed to be future-proof and expandable, the solution leverages Intel’s industry-standard, open-software platform. It will allow retailers to host a full-suite of retail applications by integrating other sensor technologies as well as third party data or applications to meet their unique demands.
IoT innovations in store layout, automated checkouts, and inventory management are expected to have up to a $1.2 trillion impact for retailers worldwide by 2025*. This new SGS and Intel solution delivers higher ROI for retailers by tackling fundamental issues in inventory management to improve productivity, decrease running costs and increase sales.
“SATO and Intel are connecting the dots to make big data analytics a reality for retailers,” explained Kaz Matsuyama, president and CEO of SATO Holdings Corporation. "With our software and systems integration expertise, we fill in that essential ‘last inch’ for customers in the retail space linking IoT technologies and data analytics to provide actionable insights to improve productivity, cut costs and drive sales."
A sample application will be presented at the Intel booth during the National Federation of Retailers’ Big Show in NYC January 17-19, 2016. The solutions will be commercially available during the second quarter of 2016.
To further enhance the value for customers, SGS and Intel are part of the Acuitas Digital Alliance comprised of British Telecom, Nexgen and RetailNext that jointly aims to create a future-proof solution for the digital business era with additional capacities. Another application of SGS and the Intel solution will be presented at the British Telecom booth at NRF.
For more about SGS retail IoT solutions, please visit: www.satoglobalsolutions.com/featured1.php#retail and www.intel.com/retail/rsp
*Source: McKinsey & Company, “The Internet of Things: Mapping the Value Beyond the Hype ”
Intel is a trademark of Intel Corporation in the United States and other countries.
About SATO Global Solutions
SATO Global Solutions, headquartered in Fort Lauderdale, is a subsidiary of SATO Holdings (TOKYO:6287), a Tokyo-based pioneer and global leader in auto-ID solutions. It develops comprehensive IoT solutions that address client’s unique needs by unleashing the power of data. As an “innovation integrator,” SGS combines technologies, hardware and applications that turn data into meaningful and actionable insight that enable clients to make data-driven decisions and maximize value across their business. SGS embraces the rapidly evolving IoT environment and chooses the best technologies available to create solutions that meet the specific needs of each client. For more information, visit www.satoglobalsolutions.com or www.linkedin.com/company/sato-global-solutions
About SATO
SATO (TOKYO:6287) is a leading global provider of Auto-ID solutions that connect people, goods and information. It serves a diverse range of customers, delivering end-to-end solutions that streamline operations, empower workforces and help customers reduce their environmental impact. For the fiscal year ended March 31, 2015, it reported revenues of JPY 99,831 million (US$ 910 million*). More information about SATO can be found at www.satoworldwide.com or www.linkedin.com/company/sato-worldwide .
*Conversion is based on an average exchange rate of 1 US Dollar = 109.75 Japanese Yen.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160118005230/en/
Contact:
US Media Inquiries:
SATO Global Solutions
Yasuko
Fumuro, +1 954 203 1713
Director of Global Communications
yasuko.fumuro@sato-global.com
Europe
Media Inquiries:
Marco Giudici, +44 (0)1582 390 991
Technical
Publicity
mgiudici@technical-group.com
Link:
Social Media:
http://www.facebook.com/Sato-Global-Solutions-780279485450723/?fref=nf
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Data From Landmark HELIOS-B Phase 3 Study Presented at ESC Congress 2025 Demonstrate Vutrisiran’s Long-Term Cardiovascular Benefit in ATTR-CM31.8.2025 11:15:00 CEST | Press release
− Sustained Benefit of Vutrisiran Across Mortality, Cardiovascular Events, Quality of Life and Cardiac Biomarkers Observed Through Up to 48 Months, Including 12 Months from the Ongoing Open-Label Extension, Reinforce Potential as First-Line Treatment for ATTR-CM –− Vutrisiran, which Delivers Rapid Knockdown of Transthyretin, Reduced the Risk of Composite of All-Cause Mortality or First Cardiovascular Event by 37% in the Overall Population and 42% in the Monotherapy Group During the Same Period – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced results of new analyses from the HELIOS-B Phase 3 study of AMVUTTRA® (vutrisiran), an RNAi therapeutic approved for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults. Data from the 12-month follow-up of the ongoing open-label extension (OLE) period of HELIOS-B were presented during an oral session at the European Society of Card
WETEX Opens Broad Investment Horizons for International Companies31.8.2025 08:30:00 CEST | Press release
DEWA will organise the exhibition from 30 September to 2 October 2025 Under the directives of HH Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Ruler of Dubai, and the patronage of HH Sheikh Ahmed bin Saeed Al Maktoum, Chairman of the Dubai Supreme Council of Energy, Dubai Electricity and Water Authority (DEWA) will organise the 27th edition of the Water, Energy, Technology and Environment Exhibition (WETEX) from 30 September to 2 October 2025 at the Dubai World Trade Centre. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250830023664/en/ WETEX opens broad investment horizons for international companies (Photo: AETOSWire) WETEX embodies the UAE's pioneering position in clean and renewable energy and sustainability. It also supports Dubai's ambitious vision of a sustainable economy. The exhibition covers multiple areas including water, energy, smart cities, green mobility, artificial i
Daiichi Sankyo Announces the Initiation of the Development of Oral Triple Combination Lipid-Lowering Tablets to Support the Management of LDL-C30.8.2025 18:00:00 CEST | Press release
Initiation of the development of new oral triple combination tablets, aimed at improving adherence and outcomes in low-density lipoprotein cholesterol (LDL-C) management. Recent findings from MILOS and SANTORINI registries presented at ESC Congress 2025, highlight ongoing challenges in accurately assessing cardiovascular (CV) risk and helping patients reach LDL-C targets.1-5 Furthermore, data from a four-country cohort of the MILOS study support the real-world effectiveness and safety of bempedoic acid in both sexes.6 Simulation using SANTORINI data reveals the potential of improved LDL-C goal attainment with tailored oral combination therapy of statins, ezetimibe and bempedoic acid, in line with the latest 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias.7,8 Daiichi Sankyo has a long-standing commitment to easing treatment of cardiovascular disease (CVD) and exploring new treatment options that improve CVD outcomes and treatment adherence. Daiich
Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial30.8.2025 16:30:00 CEST | Press release
- Phase 3 Trial Informed by KARDIA-3 Phase 2 Study Results Presented as a Late-Breaking Abstract at the European Society of Cardiology Congress 2025 -- Zilebesiran Demonstrated Clinically Meaningful Reductions in Office Systolic Blood Pressure in Patients with Uncontrolled Hypertension and High Cardiovascular Risk at Month 3 Primary Endpoint, with Continuous Control Through Month 6 -- Zilebesiran Displayed Encouraging Safety When Combined with Two or More Antihypertensives -- Results Support Biannual Dosing Regimen and Inform Phase 3 Trial Design: Trial Expected to Initiate by Year-End 2025 -- Alnylam to Host Webcast Investor Event on August 30, 2025, at 1:00 pm ET (7:00 pm CEST) - Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced plans to initiate a Phase 3 cardiovascular outcomes trial (CVOT) to evaluate the potential of zilebesiran to reduce the risk of major adverse cardiovascular events. This decision is informed by results from t
Andersen Consulting styrker sine kompetencer inden for virksomhedstransformation med Fabric29.8.2025 17:01:00 CEST | Pressemeddelelse
Andersen Consulting udvider sin platform gennem en samarbejdsaftale med Fabric, der er et strategisk designfirma, der arbejder med organisationer for at integrere bæredygtighed, forsyningskæder og menneske-centreret innovation på tværs af kultur og drift. Fabric blev grundlagt i Japan i 2021 og arbejder sammen med virksomheder og globale brands om at skabe regenerative forretningsmodeller sammen samt bæredygtige brandstrategier og fremtidssikrede produkter. Ved hjælp af strategiske designmetoder og designfilosofi skaber virksomheden indsigtsbaseret transformation på tværs af forsyningskæder, brand og HR. Fabric er kendt for sin systemtænkning og sit engagement i social og miljømæssig bæredygtighed og fremmer desuden digitale transformationsinitiativer, der integrerer bæredygtighed, humankapital og AI. "Fabric er skabt for at hjælpe virksomheder med at blomstre gennem regenerative relationer til mennesker, samfund og forbundne, levende systemer," sagde James Hollow, der er grundlægger a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom